MGTX
MeiraGTx Holdings plc
NASDAQ · Healthcare · Biotechnology · US
$13.89
−0.57%Aug 13, 2026, 14:26 UTC
MeiraGTx Holdings PLC reported Q2 2026 earnings of $1.71 per share, surpassing the Zacks Consensus Estimate of a loss of $0.39 per share, and compared to a loss of $0.48 per share a year ago.
Source:Aug 13, 2026, 12:00 UTC
MeiraGTx raised $100 million in equity financing concurrent with the bota-vec acquisition.
Source:Aug 13, 2026, 12:00 UTC
MeiraGTx completed the acquisition of all interests and rights to botaretigene sparoparvovec (bota-vec) from Johnson & Johnson for $25 million.
Source:Aug 13, 2026, 12:00 UTC
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of radiation-induced xerostomia.
Source:Aug 13, 2026, 00:00 UTC
MeiraGTx Holdings plc entered into a strategic investment agreement with Oberland Capital for up to $400 million, including up to $375 million in non-dilutive capital and up to $25 million in equity.
Jul 7, 2026, 11:30 UTC
MeiraGTx entered into an agreement with Oberland Capital for a $400 million investment including up to $375 million in non-dilutive capital for capped royalty payments and up to $25 million in equity.
Jul 7, 2026, 00:00 UTC
MeiraGTx Holdings plc signed a Royalty Note Purchase Agreement to issue up to $375 million of senior secured royalty notes to Maverick SA LLC and Oberland Capital Management LLC, with $125 million initially funded.